XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 98.8

Change

+0.37 (+0.38)%

Market Cap

N/A

Volume

6.83M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
XLV Health Care Select Sector SPDR..

+1.00 (+0.65%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.64%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
FXH First Trust Health Care AlphaD..

+0.42 (+0.37%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
XHE SPDR® S&P Health Care Equipme..

+0.67 (+0.75%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B
IDNA iShares Genomics Immunology an..

+0.05 (+0.22%)

USD 0.14B

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

N/A

USD 0.04B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.65% 55% F 58% F
Dividend Return 0.15% 16% F 2% F
Total Return 10.80% 55% F 50% F
Trailing 12 Months  
Capital Gain 39.84% 88% B+ 84% B
Dividend Return 0.20% 14% F 3% F
Total Return 40.05% 88% B+ 82% B
Trailing 5 Years  
Capital Gain 31.45% 31% F 61% D-
Dividend Return 0.57% 25% F 2% F
Total Return 32.02% 26% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 2.38% N/A N/A 47% F
Dividend Return 2.46% N/A N/A 37% F
Total Return 0.08% N/A N/A 3% F
Risk Return Profile  
Volatility (Standard Deviation) 32.87% N/A N/A 30% F
Risk Adjusted Return 7.50% N/A N/A 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike